Cyclin-dependent kinase and protein kinase C inhibitors: A novel class of antineoplastic agents in clinical development

Andreas Kaubisch, G. K. Schwartz

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Malignant cells have acquired adaptations, which give them a growth and survival advantage over normal cells. One effect of many of these adaptations is that many cancerous cells are less likely to undergo programmed cell death (apoptosis) and, moreover, are resistant to chemotherapy-induced apoptosis. Other features of neoplastic cells are the loss of regulated or orderly progression through the cell cycle. In normal and cancerous cells, a balance between proapoptotic and antiapoptotic signals exists. Protein kinase C (PKC) is a cellular serine/threonine kinase with a central role in the mediation of mitogenic signals as well as the regulation of anti-apoptotic signals. Inhibition of PKC by a novel group of chemical agents (PKC inhibitors) can induce apoptosis in some malignant cell lines, act as differentiating agents, and enhance the effect of cytotoxic chemotherapy. Other kinase inhibitors are potent inhibitors of kinases involved in the control of cell cycle progression (cyclin-dependent kinases [cdks]). Cdk inhibitors are able to induce cell cycle arrest in neoplastic cells and also act as enhancers of chemotherapy-induced apoptosis. The catalytic domain of different classes of kinases (PKC and cdk) share considerable homology. As a result, many kinase inhibitors that act by blocking the catalytic site are not highly specific and may act as inhibitors of both PKC and cdks. Preclinical studies point to potential applications for some of these PKC/cdk inhibitors, and current clinical trials are exploring the role these agents might have in cancer therapy. In this article, we discuss the rationale for the development of this novel class of agents and highlight those drugs, which have shown promise in clinical testing.

Original languageEnglish (US)
Pages (from-to)192-212
Number of pages21
JournalCancer Journal
Volume6
Issue number4
StatePublished - 2000
Externally publishedYes

Fingerprint

Cyclin-Dependent Kinases
Protein C Inhibitor
Protein Kinase Inhibitors
Antineoplastic Agents
Protein Kinase C
Apoptosis
Phosphotransferases
Cell Cycle Checkpoints
Drug Therapy
Catalytic Domain
Protein-Serine-Threonine Kinases
Cell Cycle
Cell Death
Clinical Trials
Cell Line
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • Alsterpaullone
  • Apoptosis
  • Bryostatin-1
  • Calphostin
  • Cancer
  • Cdk inhibitor
  • Cell cycle
  • CGP 41251
  • Cyclin-dependent kinase
  • Flavopiridol
  • GF-109203X
  • Hypericin
  • ISIS 3521/CGP 64128A
  • Kenpaullone
  • LY333531
  • PKC inhibitor
  • Protein kinase C
  • Safingol
  • Staurosporine
  • UCN-01

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cyclin-dependent kinase and protein kinase C inhibitors : A novel class of antineoplastic agents in clinical development. / Kaubisch, Andreas; Schwartz, G. K.

In: Cancer Journal, Vol. 6, No. 4, 2000, p. 192-212.

Research output: Contribution to journalArticle

@article{28ff154002bf4753a990d232b79c71b0,
title = "Cyclin-dependent kinase and protein kinase C inhibitors: A novel class of antineoplastic agents in clinical development",
abstract = "Malignant cells have acquired adaptations, which give them a growth and survival advantage over normal cells. One effect of many of these adaptations is that many cancerous cells are less likely to undergo programmed cell death (apoptosis) and, moreover, are resistant to chemotherapy-induced apoptosis. Other features of neoplastic cells are the loss of regulated or orderly progression through the cell cycle. In normal and cancerous cells, a balance between proapoptotic and antiapoptotic signals exists. Protein kinase C (PKC) is a cellular serine/threonine kinase with a central role in the mediation of mitogenic signals as well as the regulation of anti-apoptotic signals. Inhibition of PKC by a novel group of chemical agents (PKC inhibitors) can induce apoptosis in some malignant cell lines, act as differentiating agents, and enhance the effect of cytotoxic chemotherapy. Other kinase inhibitors are potent inhibitors of kinases involved in the control of cell cycle progression (cyclin-dependent kinases [cdks]). Cdk inhibitors are able to induce cell cycle arrest in neoplastic cells and also act as enhancers of chemotherapy-induced apoptosis. The catalytic domain of different classes of kinases (PKC and cdk) share considerable homology. As a result, many kinase inhibitors that act by blocking the catalytic site are not highly specific and may act as inhibitors of both PKC and cdks. Preclinical studies point to potential applications for some of these PKC/cdk inhibitors, and current clinical trials are exploring the role these agents might have in cancer therapy. In this article, we discuss the rationale for the development of this novel class of agents and highlight those drugs, which have shown promise in clinical testing.",
keywords = "Alsterpaullone, Apoptosis, Bryostatin-1, Calphostin, Cancer, Cdk inhibitor, Cell cycle, CGP 41251, Cyclin-dependent kinase, Flavopiridol, GF-109203X, Hypericin, ISIS 3521/CGP 64128A, Kenpaullone, LY333531, PKC inhibitor, Protein kinase C, Safingol, Staurosporine, UCN-01",
author = "Andreas Kaubisch and Schwartz, {G. K.}",
year = "2000",
language = "English (US)",
volume = "6",
pages = "192--212",
journal = "Cancer Journal from Scientific American",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Cyclin-dependent kinase and protein kinase C inhibitors

T2 - A novel class of antineoplastic agents in clinical development

AU - Kaubisch, Andreas

AU - Schwartz, G. K.

PY - 2000

Y1 - 2000

N2 - Malignant cells have acquired adaptations, which give them a growth and survival advantage over normal cells. One effect of many of these adaptations is that many cancerous cells are less likely to undergo programmed cell death (apoptosis) and, moreover, are resistant to chemotherapy-induced apoptosis. Other features of neoplastic cells are the loss of regulated or orderly progression through the cell cycle. In normal and cancerous cells, a balance between proapoptotic and antiapoptotic signals exists. Protein kinase C (PKC) is a cellular serine/threonine kinase with a central role in the mediation of mitogenic signals as well as the regulation of anti-apoptotic signals. Inhibition of PKC by a novel group of chemical agents (PKC inhibitors) can induce apoptosis in some malignant cell lines, act as differentiating agents, and enhance the effect of cytotoxic chemotherapy. Other kinase inhibitors are potent inhibitors of kinases involved in the control of cell cycle progression (cyclin-dependent kinases [cdks]). Cdk inhibitors are able to induce cell cycle arrest in neoplastic cells and also act as enhancers of chemotherapy-induced apoptosis. The catalytic domain of different classes of kinases (PKC and cdk) share considerable homology. As a result, many kinase inhibitors that act by blocking the catalytic site are not highly specific and may act as inhibitors of both PKC and cdks. Preclinical studies point to potential applications for some of these PKC/cdk inhibitors, and current clinical trials are exploring the role these agents might have in cancer therapy. In this article, we discuss the rationale for the development of this novel class of agents and highlight those drugs, which have shown promise in clinical testing.

AB - Malignant cells have acquired adaptations, which give them a growth and survival advantage over normal cells. One effect of many of these adaptations is that many cancerous cells are less likely to undergo programmed cell death (apoptosis) and, moreover, are resistant to chemotherapy-induced apoptosis. Other features of neoplastic cells are the loss of regulated or orderly progression through the cell cycle. In normal and cancerous cells, a balance between proapoptotic and antiapoptotic signals exists. Protein kinase C (PKC) is a cellular serine/threonine kinase with a central role in the mediation of mitogenic signals as well as the regulation of anti-apoptotic signals. Inhibition of PKC by a novel group of chemical agents (PKC inhibitors) can induce apoptosis in some malignant cell lines, act as differentiating agents, and enhance the effect of cytotoxic chemotherapy. Other kinase inhibitors are potent inhibitors of kinases involved in the control of cell cycle progression (cyclin-dependent kinases [cdks]). Cdk inhibitors are able to induce cell cycle arrest in neoplastic cells and also act as enhancers of chemotherapy-induced apoptosis. The catalytic domain of different classes of kinases (PKC and cdk) share considerable homology. As a result, many kinase inhibitors that act by blocking the catalytic site are not highly specific and may act as inhibitors of both PKC and cdks. Preclinical studies point to potential applications for some of these PKC/cdk inhibitors, and current clinical trials are exploring the role these agents might have in cancer therapy. In this article, we discuss the rationale for the development of this novel class of agents and highlight those drugs, which have shown promise in clinical testing.

KW - Alsterpaullone

KW - Apoptosis

KW - Bryostatin-1

KW - Calphostin

KW - Cancer

KW - Cdk inhibitor

KW - Cell cycle

KW - CGP 41251

KW - Cyclin-dependent kinase

KW - Flavopiridol

KW - GF-109203X

KW - Hypericin

KW - ISIS 3521/CGP 64128A

KW - Kenpaullone

KW - LY333531

KW - PKC inhibitor

KW - Protein kinase C

KW - Safingol

KW - Staurosporine

KW - UCN-01

UR - http://www.scopus.com/inward/record.url?scp=0033787348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033787348&partnerID=8YFLogxK

M3 - Article

C2 - 11038138

AN - SCOPUS:0033787348

VL - 6

SP - 192

EP - 212

JO - Cancer Journal from Scientific American

JF - Cancer Journal from Scientific American

SN - 1528-9117

IS - 4

ER -